Technology Offer Form
*Title: Darbepoetin Production Cell Line
*Author:
*Creation Date:
*Desired Mode of Technology Offer:
Technology Type:
06.May 2013
Process / Material
Dr. M. Frey
Technology (Knowhow) Transfer / Production License /
OEM Manufacturing
Promotional Description :
Darbepoetin (Aranesp) CHO Suspension cell line. High level Darbepoetin expression in chemically defined
medium (protein and peptide free). Production in 10 liter bioreactor > 0.5 g/liter. Up- and downstream process
available.
IGAMI Production cell line development (for the production of generic proteins)
IGAMI cell lines / cellular assays (adherent cell lines for screening of inhibitors / focus: ion channel cell lines)
Technology Benefits Summary, Differentiation & Uniqueness:
IGAMI Expression system has the following benefits over conventional expression systems:
IGAMI Technology uses special DNA sequences which were co-integrated in the chromatin of the host cell leading
to a higher expression level and higher expression stability. The proprietary technology is covered by a patent. The
IGAMI Technology has been used successfully in development of a Darbepoetin production cell line as well as in
development of several ion channel expressing cell lines.
Application & Potential Advantages:
IGAMI production cell lines (suspension cell line)
-High expression level without gene amplification, resulting in a fast cell generating process
-Expression is more stable over several generations
-CHO production cell line growth up to high cell densities(extremely low lactate formation)
IGAMI cell lines (adherent for cellular assays)
-stable expression of difficult ion channel proteins
-fast cell line development
-IGAMI expression system available as inducible system
-IGAMI life cell imaging
Development Stage & Development Status Summary:
Darbepoetin cell line / up stream and downstream process available.
Technology Offer Form
Intellectual Property (if any) Please give Patent Summary:
WO2008116931
The present invention relates to polynucleotides comprising a first nucleic acid sequence for a chromatin element,
which is capable of enhancing expression, and at least one second nucleic acid sequence comprising a curved origin
motif. Furthermore, the invention relates to a host cell, a non-human transgenic organism, a vector and a kit
comprising the aforementioned polynucleotide. Moreover, the invention relates to methods for expressing a
polynucleotide of interest.
Technical Details:
Time for production cell line development depends on gene of interest.
Collaboration Description, Terms & Restrictions & Seller Support (technical / training /
documentation etc.):
IGAMI production cell line development will be done in a co-operation with a German company (GMP
certificated) which offers process development (up- and down-stream) for recombinant protein production (generic
drugs).
For Any other Enquiries regarding this technology please contact
Reply To:
J Sreedevi
Sr. Executive- Technology & Innovation
Steinbeis Centre for Technology Transfer India
8-2-603/B/S/1/1, Plot no.1, IInd Floor.
Road no 10, Banjarahills,
Hyderabad 500034, India
E-mail: tech-mktg@steinbeisindia.com
Ph - 040- 32212456, 23350285